|
Study (reference)
|
Disease
|
No.
|
Treatment
|
ORR
|
CR
|
OS
|
PFS/DFS
|
|---|
|
Phase II [67]
|
Newly diagnosed stage IV, relapsed/refractory
|
38
|
SMILE
|
79%
|
45%
|
1-year: 55%
|
1-year: 53%
|
|
Retrospective [68]
|
Newly diagnosed stage IV
|
26
|
SMILE
|
NR
|
54%
|
5-year: 47%
|
4-year: 60%
|
|
Phase III [74]
|
Newly diagnosed, advanced stage
|
21
|
DDCP
|
95%
|
71%
|
1-year: 90%
|
1-year: 86%
|
|
21
|
SMILE
|
67%
|
29%
|
1-year: 57%
|
1-year: 38%
|
|
Phase II [75]
|
Newly diagnosed, advanced stage
|
22
|
IMP L-asp
|
90%
|
65%
|
1-year: 76%
|
1-year: 43%
|
|
Phase II [76]
|
Relapsed/refractory
|
19
|
AspaMetDex
|
78%
|
61%
|
2-year: 40%
|
2-year: 40%
|
|
Retrospective [68]
|
Relapsed/refractory
|
44
|
SMILE
|
77%
|
66%
|
5-year: 52%
|
4-year: 68%
|
|
Retrospective [77]
|
Relapsed/refractory
|
13
|
MEDA
|
77%
|
61%
|
1-year: 69%
|
1-year: 62%
|
|
Retrospective [84]
|
Relapsed/refractory
|
7
|
Pembrolizumab
|
100%
|
71%
|
NR
|
NR
|
-
No. number of patients, ORR overall response rate, CR complete response, OS overall survival, PFS progression-free survival, DFS disease-free survival, SMILE dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide, DDCP dexamethasone, gemcitabine, cisplatinum, pegasparaginase, IMP L-asp ifosfamide, methotrexate, etoposide, prednisolone, L-asparaginase, AspaMetDex L-asparaginase, methotrexate, dexamethasone, MEDA methotrexate, etoposide, dexamethasone, L-asparaginase
